Regeneron Pharmaceuticals Inc (REGN)

394.90
NASDAQ : Health Care
Prev Close 394.90
Day Low/High 0.00 / 0.00
52 Wk Low/High 329.09 / 605.93
Avg Volume 892.50K
Exchange NASDAQ
Shares Outstanding 105.08M
Market Cap 41.12B
EPS 6.20
Div & Yield N.A. (N.A)

Latest News

3 Stocks Pulling The Health Care Sector Downward

3 Stocks Pulling The Health Care Sector Downward

TheStreet highlights 3 stocks pushing the health care sector lower today.

Regeneron Pharmaceuticals Becomes #41 Most Shorted Nasdaq 100 Component, Replacing Vertex Pharmaceuticals

Regeneron Pharmaceuticals Becomes #41 Most Shorted Nasdaq 100 Component, Replacing Vertex Pharmaceuticals

The most recent short interest data has been released for the 06/30/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

5 Stocks Set to Soar on Bullish Earnings

5 Stocks Set to Soar on Bullish Earnings

These heavily shorted stocks could get squeezed much higher if they report positive earnings this wee.

Award-Winning Chef Elizabeth Falkner Reveals Her Struggle With Atopic Dermatitis To Highlight The Physical And Psychological Impact Of The Disease

Award-Winning Chef Elizabeth Falkner Reveals Her Struggle With Atopic Dermatitis To Highlight The Physical And Psychological Impact Of The Disease

Falkner has joined forces with Regeneron and Sanofi Genzyme in collaboration with leading dermatology organizations to educate Americans about a potentially serious, chronic inflammatory skin disease known as atopic dermatitis

CELG, REGN, DPZ: Jim Cramer's Views

CELG, REGN, DPZ: Jim Cramer's Views

Cramer shares his views on why something could be up in biotech, restaurants and retail. Celgene, Regeneron and Domino's are among the stocks discussed.

Cramer: Might Something Be Brewing in 3 Downtrodden Sectors?

Biotech, restaurants and retail have been left for dead but are showing signs of life today.

Biotech Stock Mailbag: Mid-Year Assessment, Where We Go From Here

Biotech Stock Mailbag: Mid-Year Assessment, Where We Go From Here

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

Regeneron Pharmaceuticals Becomes #209 Most Shorted S&P 500 Component, Replacing Assurant

Regeneron Pharmaceuticals Becomes #209 Most Shorted S&P 500 Component, Replacing Assurant

The most recent short interest data has been released for the 06/15/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Regeneron Tries to Recover From Lows

Prices pop today, but is this a reversal?

Biotech Stocks Rally on Medicare Cost-Cutting Stand-Down

Biotech Stocks Rally on Medicare Cost-Cutting Stand-Down

Biotech stocks rallied in relief Wednesday after a Medicare mechanism to cut drug spending was not triggered.

'Mad Money' Lightning Round: Buy, Buy, Buy Medtronic

'Mad Money' Lightning Round: Buy, Buy, Buy Medtronic

Cramer sees Micron Technology getting back to $15 and urges caution on Holly Energy Partners.

Jim Cramer's 'Mad Money' Recap: Today's Rally Was Good but We Need More

Jim Cramer's 'Mad Money' Recap: Today's Rally Was Good but We Need More

The markets really need to see the financials, technology and healthcare sectors to move as they make up the bulk of our economy, says Jim Cramer.

3 Drugs Stocks Driving The Industry Higher

3 Drugs Stocks Driving The Industry Higher

TheStreet highlights 3 stocks pushing the drugs industry higher today.

Should You Listen to the Rich?: Jim Cramer’s Best Blogs

Should You Listen to the Rich?: Jim Cramer’s Best Blogs

Jim Cramer talks about how you shouldn't listen to the rich, except for Carl Icahn. Maybe.

3 Drugs Stocks Dragging The Industry Down

3 Drugs Stocks Dragging The Industry Down

TheStreet highlights 3 stocks pushing the drugs industry lower today.

Jim Cramer's 'Mad Money' Recap: How to Handle Your Finances at Any Age

Jim Cramer's 'Mad Money' Recap: How to Handle Your Finances at Any Age

You need to have money invested in the stock market, whatever your age, Cramer says.

Regeneron Selected By Society For Science & The Public As New Sponsor Of The Science Talent Search

Regeneron Selected By Society For Science & The Public As New Sponsor Of The Science Talent Search

Regeneron's $100 million, 10-year commitment supports the competition and STEM outreach and equity programming

3 Stocks Raising The Drugs Industry Higher

3 Stocks Raising The Drugs Industry Higher

TheStreet highlights 3 stocks pushing the drugs industry higher today.

Regeneron Pharmaceuticals (REGN) Stock is the ‘Chart of the Day’

Regeneron Pharmaceuticals (REGN) Stock is the ‘Chart of the Day’

Regeneron Pharmaceuticals (REGN) stock was chosen as the ‘Chart of the Day’ on Wednesday as its chart shows a bullish pattern.

Regeneron May Cure the Market Blues

A potentially bullish pattern is setting up. 

Chart of the Week: Regeneron

A potentially bullish pattern is setting up.

Regeneron's Spike Not Tied to Pfizer-Anacor Deal, but It Doesn't Hurt

Regeneron's Spike Not Tied to Pfizer-Anacor Deal, but It Doesn't Hurt

Dupilumab, an eczema therapy awaiting FDA approval, is arguably the most important pipeline drug for Regeneron.

Jim Cramer -- Quick Take on 30 Stocks and What Investors Are Missing

Jim Cramer -- Quick Take on 30 Stocks and What Investors Are Missing

This is the final of a two-part series in which Jim Cramer comments on each of the 30 Dow components.

How to Trade 5 Biotech Stocks After a Fall -- Plus Jim Cramer's Take

How to Trade 5 Biotech Stocks After a Fall -- Plus Jim Cramer's Take

Biotech companies Amgen, Biogen, Celgene, Gilead and Regeneron have had a volatile ride so far in 2016. These technical charts show how to trade them.

How to Trade Regeneron's Pullback

Aggressive traders can go long REGN on the first up day.